A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT03188666 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG: REGN2477
DRUG: Matching placebo

Sponsor

Regeneron Pharmaceuticals